Browse all Channels
Veracyte, Inc.

Veracyte, Inc.
6000 Shoreline Court Suite 300 ,
South San Francisco ,
California 94080
USA
  2. Companies
  3. Veracyte, Inc.
  4. Products
  5. Model Decipher - Prostate Genomic ...
Model Decipher - Prostate Genomic Classifier

Model Decipher - Prostate Genomic Classifier

0
Providing clarity and confidence in treatment planning. The Decipher Prostate (Decipher Prostate Biopsy and Decipher Prostate RP) genomic classifier is a 22-gene, whole-transcriptome-developed test designed to help inform treatment decisions for men with localized prostate cancer at initial diagnosis and after surgical removal of the prostate. The test reports the Decipher Score, which prognosticates a patient's risk of metastasis within five years and provides risk estimates of prostate cancer-specific outcomes.

Details

The Decipher Prostate genomic classifier is currently being investigated in seven National Cancer Institute-sponsored, phase 3, prospective, randomized controlled clinical trials; 13 phase 2/3 prospective trials; and more than 20 retrospective studies of phase 3 randomized controlled trials. Many of these trials require Decipher Prostate testing for study inclusion.


Decipher® Prostate Genomic Classifier
The Decipher Prostate Biopsy test is used for patients following a cancer diagnosis to inform whether the patient is a candidate for active surveillance, needs monotherapy or may benefit from multi-modality or intensified therapy. The Decipher Prostate RP test is used following surgery to guide decision-making regarding treatment timing and whether patients undergoing salvage radiotherapy may benefit from the addition of hormone therapy or may safely avoid hormone therapy and its side effects.

Customer reviews

No reviews were found for Model Decipher - Prostate Genomic Classifier. Be the first to review!